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Assessment of pathological 
response to therapy using lipid 
mass spectrometry imaging
Nathan Heath Patterson1,*, Balqis Alabdulkarim2,3,*, Anthoula Lazaris2,3, Aurélien Thomas4,5, 
Mieczyslaw M. Marcinkiewicz6, Zu-hua Gao3,7, Peter B. Vermeulen8, Pierre Chaurand1 & 
Peter Metrakos2,3
In many cancers, the establishment of a patient’s future treatment regime often relies on 
histopathological assessment of tumor tissue specimens in order to determine the extent of the 
‘pathological response’ to a given therapy. However, histopathological assessment of pathological 
response remains subjective. Here we use MALDI mass spectrometry imaging to generate lipid 
signatures from colorectal cancer liver metastasis specimens resected from patients preoperatively 
treated with chemotherapy. Using these signatures we obtained a unique pathological response score 
that correlates with prognosis. In addition, we identify single lipid moieties that are overexpressed in 
different histopathological features of the tumor, which have potential as new biomarkers for assessing 
response to therapy. These data show that computational methods, focusing on the lipidome, can be 
used to determine prognostic markers for response to chemotherapy and may potentially improve risk 
assessment and patient care.
Many solid tumors (colon cancer, breast cancer, gastric cancer, oesophageal cancer etc.) receive neoadjuvant 
chemotherapy prior to resection and the prognosis of the patient as well as the adjuvant therapeutic strategy is 
determined by the pathologic response to the neoadjuvant regime. Thus, the development of objective and quan-
titative strategies to evaluate pathologic response is important in many solid tumors.
Despite advances in management of colorectal cancer liver metastasis (CRCLM) patients, the majority are 
incurable1–3. Surgical resection is the only chance for cure but only feasible in 15–20% of patients4,5. Various 
clinical parameters such as the number and size of lesions, disease free interval, and serum Carcinoembryonic 
antigen levels, among others have been used to prognosticate these patients. However, with modern day thera-
pies including preoperative chemotherapy and loco-regional modalities, these factors no longer correlate effec-
tively with post-operative disease free and overall survival rates6–9. Similarly, clinical scoring systems that utilize 
these parameters are no longer appropriate, in that even patients with a poor clinical risk score that have a good 
response to neoadjuvant chemotherapy will have a better outcome than the clinical risk score would have pre-
dicted10,11. There are only a few molecular biomarkers that can predict prognosis and guide treatment12,13. These 
include KRAS that is used to select patients for treatment with anti-EGFR agents and microsatellite instability that 
is a prognostic factor and a marker for response to 5-FU14,15.
Pathological evaluation can predict patient outcome by assessing response to preoperative chemotherapy but 
can also evaluate surrounding unaffected liver parenchyma for chemotherapy associated toxicity that could lead 
to morbidity, further driving the choice of future chemotherapy and patient management16,17. Pathological grad-
ing systems have been developed to address this with variable correlation with survival18–22. Early post chemo-
therapy grading systems looked at percent viable tumor cells and more recently the Tumor Regression Grade 
(TRG)21 demonstrates a correlation with patient outcomes. This grading takes into consideration the degree of 
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fibrosis and necrosis in relation to tumor viability, in which fibrosis is considered a positive indicator and necrosis 
a negative indicator of response20. However with the widespread use of Bevacizumab, an angiogenesis inhibitor 
precipitating tumor necrosis as a form of response, the Modified Tumor Regression Grade (mTRG) emerged23. 
mTRG differentiates between two types of necrosis seen in resection specimens; usual necrosis (UN), typical of 
tumor progression, and infarct-like necrosis (ILN), a response to treatment, whose presence has been associated 
with favourable prognosis23. However, the pathological evaluation process remains a subjective semi-quantitative 
one regardless of which grading system is applied and is subsequently vulnerable to inter-pathologist variability 
necessitating a complementary technical approach24,25. In addition, the final pathological report can take between 
7–14 days, depending on the institution.
We propose to compliment pathologic assessment of CRCLMs with matrix-assisted laser desorption/ion-
ization (MALDI) mass spectrometry imaging (MSI). MSI images biomolecules including proteins and lipids 
directly on thin tissue sections of clinical origin maintaining spatial orientation26–29. MSI acquires mass spectra at 
defined 2-D positions across a surface and reconstructs these data into ion distribution maps reflecting molecular 
distributions30,31. Phospholipids are of clinical interest due to their biological roles in both physiological states 
and cancer processes32. The potential clinical utility of phospholipid MSI has been demonstrated in a number of 
applications32–35, however, tissue studies with large cohorts still require robust and validated approaches for data 
interpretation due to the highly multivariate nature of MSI datasets and the inherently complex nature of biolog-
ical tissue36. Currently, two approaches exist for analyzing clinical MSI data: Histology-driven MSI approaches 
where one determines MSI regions of interest based on histopathology annotations of stained serial sections, 
and histology-independent approaches where regions of interests are determined from multivariate molecular 
patterns inherent to the MSI data37. Upon isolating and validating signal patterns found in tissue, MSI offers the 
capability to automatically classify the topography of new samples38. When a sufficient spectral library has been 
generated and correlated with pathology and/or clinical outcomes, MSI data can then be further mined for poten-
tial disease biomarkers. Thus MSI can complement a subjective pathology assessment where histopathological 
areas are defined using a computational, less prone to human bias, assessment of pathological areas within tissue. 
Equally important is that this methodology can generate a numerical output within a fraction of the time that it 
takes to deliver a conventional, semi-quantitative pathology report in most clinical institutions.
Here we describe the use of MSI to grade response in clinical CRCLM tissues. Importantly, the MSI generated 
grading reflected disease progression and overall survival. In addition, we demonstrate that this methodology can 
identify unique lipid distributions and moieties that could potentially be used as prognostic markers, therapeutic 
targets, and help in further understanding the biology of CRCLM.
Results
Workflow employed in the study. Our workflow is briefly outlined in Fig. 1: it begins with MSI data 
acquisition from CRCLM specimens in both positive and negative ionization mode (step 1). The raw spectral 
data is pre-processed by total-ion-current (TIC) normalization and then peak picked followed by spatially-aware 
k-means segmentation of the peak data. (step 2). The generated segments are correlated visually with the major 
histological compartments within the sample using multiple stained serial sections of the tissue. The correlated 
segments are trained to partial least squares–discriminant analysis (PLS-DA) algorithm. This completes the his-
tology driven part of the workflow, ending with a spectral library and PLS-DA classifier (step 3). The lipid sig-
natures are then validated by classifying an independent cohort of specimens. The resulting classification can be 
used to compute an mTRG grading for direct clinical application that is less subjective than classic pathology. 
Finally, while multivariate analysis of the data allows classification of new samples, univariate examination of the 
data identifies histologically discriminating species with potential clinical or fundamental impact.
After development of a training set, sample throughput is limited to the time of sample preparation, data 
acquisition, pre-processing and classification. Sample preparation for one sample including cutting and matrix 
sublimation should take anywhere from 30–90 minutes. Data acquisition on the instrument used in this study 
was at a speed of 2 pixels/s, generally around 1 to 2 hours for an average sized sample. Next generation MALDI 
systems are routinely capable of 25+ pixels/s with some up to 50 pixels/s. At this acquisition speed a sample of 
1 cm2 at 100 μ m of spatial resolution would take only a matter of minutes. Finally, data processing including nor-
malization and peak picking will take approximately an hour.
Correlation of Histopathology to Mass Spectrometry Imaging. Our first goal was to determine 
whether signatures derived from MSI data are capable of robustly distinguishing different histopathological fea-
tures of CRCLM tumor specimens. To achieve this, a training set of 12 CRCLM specimens from 12 patients were 
analyzed by MSI using sublimated DAN matrix with no sample preparation beyond cutting and desiccation of 
the tissue sections. All MSI results are only relatively quantitative in the mass spectrometric sense; no internal 
standards have been used. After pre-processing, the acquired MSI spectra were segmented using spatially aware 
k-means. This algorithm incorporates spatial data into the clustering analysis by considering similarity between 
neighbouring pixels during computation. The algorithm is implemented in the Cardinal R package, and we used 
a pixel radius of 1 for all segmentation. The generated segments were then correlated to tumor morphology by 
visual comparison with H&E-stained sections of the same specimens. This methodology required expert pathol-
ogy in order to determine the best segment correlation for each histological region. Using 100 micron MSI res-
olution, gross tissue regions were assessed rather than the intricacies apparent through optical microscopy of 
stained sections. Liver lesions ranged in size from 0.3 to 9.2 cm with a mean size of 4.7 cm. The mean follow up 
for this cohort of patients was 30.2 months. Overall survival (OS) and disease free survival (DFS) by the end of 
the study period in this group of patients was 81.8% and 48.6% respectively. Relevant clinical data is presented in 
supplementary Table S1 and Figure S1. The clinical data highlights the diversity of the cohort.
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Figure 2 illustrates MSI segmentation of a tissue section from the training set, visually correlated to an H&E 
stain of the same section presented here at low magnification (2A). Segmentation of the data into 7 molecular 
signatures (k = 7) was able to identify 6 histopathological features of the tumor and surrounding areas within 
the training set, as one cluster defines MALDI matrix noise. We have color coded the 6 signatures (a signature is 
defined as a combination of lipids and intensity unique to a histopathology) as: adjacent unaffected liver (blue), 
tumor (red), necrosis (purple), fibrosis (grey), inflammation (green) and mucin/MALDI matrix noise (white). 
Segmentation algorithms provide an unsupervised means of data reduction and when correlated to histology, 
prevent analysis of irrelevant MSI pixels that may occur with manual selection of ROIs in spatially heterogeneous 
MSI data. It also aids in the comparison of histologies across a cohort (i.e. comparison of tumor cells from one 
sample to another). The segmentation data for each sample in the training set is shown in the rightmost column 
of Figure S2 (higher magnification in Figure S3) while the battery of histological staining are in the adjacent 
columns.
A tile plot of average peak intensity shows univariate comparisons of 14 top marker ions for the correlated 
topographies (Fig. 2B). Receiver operator characteristic (ROC) curves were calculated for all picked peaks and the 
calculated area under the curve (a.u.c.ROC) determined the most discriminant. ROC curves measure the ability 
of a given signal to classify histology versus all others by determining the overlap of signal distribution between 
two sets of observations. In our case, observations were compared by pixels from one histology vs. a random sub-
set of pixels from all other histologies, effectively removing markers that discriminate multiple histologies. These 
Figure 1. Summary of workflow. a.i. = arbitrary intensity.
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data reveal a selection of lipid species that are histologically discriminant and have a higher probability of being 
implicated in the tumor biological processes. Figure 2C shows mean picked peak data from the various histologies 
with the same color coding showing the peak intensity overlap for some histologies. These plots demonstrate a 
difficult when using single markers that are not unique in classification and the necessity of multivariate methods. 
Table 1 indicates the most discriminant species’ topographies, masses, a.u.c.ROCs, fold changes, identity, and 
characteristic MS/MS ions as identified through on tissue MS/MS (Individual ion images and annotated MS/MS 
spectra of the top markers are presented in Figures S4 and S5).
These data show that MSI signatures discriminate different histopathological features of CRCLM specimens. 
Finally, the collation of the histological and MSI data allowed us to generate a spectral library from these samples 
where each spectrum had a corresponding histological designation.
Validation of Lipid signatures. We used the spectral library developed from the training set to classify 
the topography of 40 additional specimens by PLS-DA. The MSI classified lipid segmentations of this cohort of 
specimens (Fig. 3A–C, representatives of 3 specimens) were validated by comparing a pathologist scoring of each 
specimen’s high resolution H&E scans (Fig. 3E–L) for the different histologies. This was done using side-by-side 
images of classified segmentation data and serial H&E data, where the pathologist noted the general correlation. 
Comparison of the MSI and pathologist’s assignment of tissue types showed strong correlation between the two 
(Fig. 3M–O, representing pathology score). For example, the sample in Fig. 3A MSI shows large areas of tumor 
cell segmentation (red coloring) indicating tumor cells verified by the H&E stain (Fig. 3D,J: magnified tumor 
area, tumor cells apparent by their deep purple haematoxylin stain, and in the case of differentiated CRC cells, 
their glandular shape). Within the dense tumor cell areas, there are small areas of tumor stroma with inflamma-
tion (Fig. 3D, indicated by arrow) evident in the H&E by their lighter pink stain, and many small monocytes, indi-
cated as small circular cells in the staining, that are also well classified by MSI as inflammation (Fig. 3A, indicated 
by arrow, green segment in Fig. 3A).
Each lesion’s MSI classification was scored from 1 to 5, 1 indicating 1/5th of the histology matching and 5/5th 
complete correlation. These correlations are presented for the individual samples in the far right area of Fig. 3; 
panels M, N and O. MSI identified distinct lipid signatures distinguishing areas of fibrosis and inflammation. 
However, the pathologist was not able to evaluate the amount of inflammation if it was mixed within fibrosis 
(inflammatory fibrosis) on H&E staining, as further special staining is needed to differentiate between these his-
tologies. The adjacent unaffected liver (blue), tumor (red), necrosis (purple), fibrosis/inflammation (grey/green) 
and loose tissue mucin (white) segments scored an average of 5, 4.9, 4.5, 4.9, and 4.7 respectively indicating a 
Figure 2. Correlation of MSI to histological staining and mining MSI data. (A) Visualization of the 
workflow employed comparing MSI segmentations to staining of serial sections. Color scheme of various 
detected regions is given below. (B) Tile plot of signal intensity of averages of 14 most discriminant markers 
from MSI listed by correlated histology. (C) Average of training set peak intensity from all pixels within the 
correlated histology from positive and negative ionization modes, top and bottom, respectively. Colors are as 
presented in section A. (a.u.) = arbitrary units.
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very high level of correlation between the MSI prediction of all histologies in this cohort of specimens. These 
correlative results based on serial sections are still useful as although many microscopic features of the tissue 
section change in serial sections, the macro regions change only moderately, allowing comparison at this res-
olution. Necrotic tissue had the lowest correlation of the major regions studied herein, and this may be due to 
histopathological uncertainty concerning necrotic tissue. However, the necrotic regions identified by MSI were 
molecularly distinct.
Classifications for a subset of our cohort (n = 22) with their validation score using the system described above 
are available in Figure S6 along with H&E staining of serial sections for comparison. One should note that the 
pathologist’s evaluation was performed visually and compared to our color schemes for each histology; therefore 
an absolute quantitation is not possible. Despite this reality, the correlations between MSI classification and his-
topathology were high.
Mining of the necrosis segmentation identified the two distinct types of necrosis. We next eval-
uated whether MSI signatures can discriminate different types of necrosis in tissue specimens. In CRCLMs, two 
types of necrosis have been described; Infarct-Like Necrosis (ILN) and Usual Necrosis (UN). ILN is characterized 
by confluent areas of strong eosin staining while UN, found within tumor cell glands, also stains strongly with 
eosin, but is patchier and mixed with nuclear debris. Further, a ring of fibrosis sometimes surrounds ILN, whereas 
UN is found within the glands of colon cancer cells. ILN has been correlated with response to treatment and 
better prognosis, whereas UN is considered a normal process of tumor cell proliferation and is associated with a 
worse patient outcome23.
Mining the necrosis MSI lipid signature revealed lipids that differentiated the above-mentioned types of 
necrosis. Figure 4A shows a classified MSI sample with a necrotic areas indicated in purple. We identified sev-
eral of the species distinguishing ILN and UN in positive ionization mode with the most intense being sphin-
gomyelin 16:0 (SM(d18:1/16:0), m/z 703.57), abundant in ILN (Fig. 4B, red) and several plasmalogen species 
(including PC(p-(16:0/18:1) and PC(p-18:0/18:3) at m/z 744.59 and m/z 765.57. Table.1, Figure S7, more abun-
dant in UN (Fig. 4B, green). These areas were confirmed using high-magnification H&Es (Fig. 4 C–E). In negative 
ionization mode, we identified C16 ceramide (Cer(d18:1/16:0), m/z − 536.50) to be abundant in UN and C16 
Topography m/z Identity Fold change a.u.c.ROC MS/MS
Normal NEG_738.5 PE(16:0/20:4) 3.161 ± 0.23 0.923 FA-1:255, FA-2:303, 434(Etn), 452(Etn)
 NEG_762.5 PE(16:0/22:6) 4.827 ± 0.45 0.940 FA-1:255, FA-2:327, 434(Etn), 452(Etn), 506(Etn), 524(Etn)
 NEG_885.56 PI(18:0/20:4) 3.227 ± 0.19 0.964 303, 283 (fatty acyl chains), 297 (Glycerophosphoinositol), 241 (Inositol phosphate ion)
 POS_758.57 PC(16:0/18:2) 2.71 ± 0.66 0.996 Li_fragmentation: 508(NL of 16:0), 484(NL of FA 18:2), 508(NL of 16:0), NL of 59, NL of 183 (PC headgroup)
Tumor NEG_698.48 PE(p-16:0/18:2) 2.408 ± 0.42 0.878 FA-2: 279, 436 (Loss of sn2 acyl chain as ketene (RCH = C = O) from [M-H]-)
 NEG_700.51 PE(p-16:0/18:1) 2.151 ± 0.52 0.864 FA-2: 281, 436 (Loss of sn2 acyl chain as ketene (RCH = C = O) from [M-H]-)
 NEG_835.54 PI(16:0/18:1) 2.813 ± 0.63 0.885 281, 255 (fatty acyl chains), 297 (Glycerophosphoinositol), 241 (Inositol phosphate ion), 673(NL of inositol)
 POS_706.55 PC(14:0/16:0) 2.835 ± 0.51 0.829 184(PC headgroup), ~0.7 ppm error
 POS_732.55 PC(16:0/16:1) 5.355 ± 1.29 0.921 Li_fragmentation: 480(NL of 16:1), 482(NL of 16:0), NL of 59, NL of 183 (PC headgroup)
Inflammation NEG_722.49 PE(p-16:0/20:4) 3.749 ± 0.62 0.935 436(Loss of sn2 acyl chain as ketene (RCH = C = O) from [M-H]-), 303(FA chain)
 NEG_750.53 PE(p-18:0/20:4) 3.744 ± 0.66 0.845 464 (Loss sn2 acyl chain as ketene (RCH = C = O) from [M-H]-), 303(FA)
 POS_734.57 PC(16:0/16:0) 3.673 ± 0.72 0.942 Li_fragmentation: 478(NL of 16:0), NL of 59, NL of 183 (PC headgroup)
Fibrosis POS_782.55 PC(18:2/18:2) 1.5 ± 0.61 0.780 184(phosphatidylcholine headgroup)
Infarct-like Necrosis POS_703.57 SM(d18:1/16:0) 5.62 ± 0.66 0.902 Li_fragmentation: 280(sn-2 loss), NL of 59, NL of 183 (PC headgroup)
 NEG_616.47 Cer-1-P(d18:1/16:0) 4.83 ± 1.12 0.880 96(phosphate group), 78(phosphate-H2O)
Usual Necrosis POS_742.57 PC(p-16:0/18:2) 2.20 ± 0.43 0.823 Li_fragmentation: NL of 189 (PC headgroup), 279(NL of 189 + NL of non-plasmenyl FA)
 POS_744.59 PC(p-16:0/18:1) 5.16 ± 1.14 0.911 Li_fragmentation: NL of 189 (PC headgroup), 279(NL of 189 + NL of non-plasmenyl FA)
 POS_746.59 PC(p-16:0/18:0) 5.56 ± 0.78 0.912 Li_fragmentation: NL of 189 (PC headgroup), 279(NL of 189 + NL of non-plasmenyl FA)
 POS_768.57 PC(p-18:0/18:3) 5.02 ± 0.98 0.902 Li_fragmentation: NL of 189 (PC headgroup), 307(NL of 189 + NL of non-plasmenyl FA)
 POS_770.59 PC(p-18:0/18:2) 3.94 ± 0.74 0.872 Li_fragmentation: NL of 189 (PC headgroup), 307(NL of 189 + NL of non-plasmenyl FA)
 POS_772.59 PC(p-18:0/18:1) 3.54 ± 0.88 0.854 Li_fragmentation: NL of 189 (PC headgroup), 307(NL of 189 + NL of non-plasmenyl FA)
 NEG_536.50 C16 Cer(d18:1/16:0) 4.83 ± 1.19 0.945 506(NL of H2CO), 504(NL of H2-H2CO), 488(NL of H2O-H2CO), 296(side chain loss), 254(FA loss)
Table 1.  Table of characteristic ions. Fold change and area under the ROC calculated vs all other histologies. 
Etn = ethanolamine. NL = neutral loss. FA = fatty acid. PC = phosphatidylcholine. PE = phosphoethanolamine. 
SM = Sphingomyelin. p-16:0/p-18:0 = plasmenyl lipid. Cer = Ceramide. PI = phosphoinositol.
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ceramide-1-phosphate (Cer-1-P(d18:1/16:0), m/z − 616.47) to be abundant in ILN. These species were identified 
through on tissue MS/MS fragmentation and their fragmentation spectra and scheme are available in Figure S8. 
Salient statistical information for these markers is available in Table 1.
These data demonstrate that MSI signatures can successfully discriminate different types of necrosis (ILN and 
UN) in tissue specimens that may not be clear by histopathology. Further, the use of both positive and negative 
ionization modes increased the number of discriminant species and indeed, sphingomyelin found in positive 
mode is related to the ceramide species in negative mode. This result hints at the fundamental tumor biology 
underlying necrosis by imaging ceramide directly and potential downstream or precursor species sphingomyelin 
and ceramide phosphates.
Exploring clinical application/relevance of an automated recognition-based lipid-signature 
image analysis. To evaluate the robustness and clinical utility of MSI classifications, we calculated an 
mTRG score based on MSI classification data. mTRG is a CRCLM tumor grading system that scores sections 
stained by H&E based on the presence and amount of the following histologies: viable tumor cells, usual necrosis, 
infarct-like necrosis and fibrosis. We implemented the published mTRG guidelines20,23 (summarized in Table 2) 
into an algorithm and applied to our data. Since pathological response assessed by mTRG does not require the 
differentiation between the two, the MSI fibrosis (grey) and inflammation (green) segments were treated as one 
in the calculation of mTRG. The scores for all the specimens (n = 52) were correlated with scores of two inde-
pendent, blinded pathologists (Table S2). Inter-pathologist correlation was observed at r = 0.7361 (p < 0.0001, 
Table 3). The MSI generated scores correlated with both pathologists (r = 0.8121 and r = 0.6227, for pathologist 
1 and 2, respectively, (p < 0.0001), Table 3). To demonstrate clinical relevance, we plotted the mTRG grades from 
the pathologist and MSI classification to OS and DFS curves. Patients who received chemotherapy (n = 35) were 
stratified into three response groups according to their scores (major response: grades 1 and 2, partial response: 
grade 3, and minor response: grades 4 and 520). Three-year OS and DFS were calculated for each group and 
we observed comparable outcomes in all three grading’s (Pathologist 1, Pathologist 2 and MSI lipid signatures, 
Fig. 5). These data confirm that MSI can be used to provide prognostically useful information with potential 
time–saving and automation of the entire process.
Figure 3. Partial Least Squares-Discriminant Analysis classifications of tissue topography (3 representative 
samples classified based on the previously extracted segmentations). Box (A–C) classified MSI image. (D–F) 
low-magnification (0.4x) H&E staining of serial section. (G–L) H&E staining of two areas from serial sections 
(high magnification, 4.0x); (G) enlargement of Blue box from D showing area of necrosis; (J) enlargement of 
Red Box from D showing tumor cells; (H,I) enlargement of Blue boxes from (E,F) respectively showing small 
foci of tumor; (K,L) enlargement of Red boxes from (E,F) respectively showing small foci of tumor; (M–O) 
Pathology correlation score. Arrows in Box (A,D) show small inflammation areas within tumor.
www.nature.com/scientificreports/
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Discussion
A challenge in the treatment of patients is the assessment of their response in an objective and quantitative man-
ner39. Currently a clinician relies on both the pathologist and radiologist’s assessments, which remain subjective 
and differs based on experience. Pathologist assessments rely on “eye-ball” estimates of tumor burden and with 
the introduction of mTRG (differentiating the two types of necrosis) its subjectivity has been driven further. 
Working towards more objective patient assessments, we have succeeded in converting the mTRG from a subjec-
tive semi-quantitative grading system into a computational model that calculates a mTRG score from numerical 
Figure 4. MSI detection of infarct-like necrosis (ILN) and usual necrosis (UN). (A) MSI classification of 
sample, thin left arrow in ILN, fat right arrow in UN. (B) Positive ionization mode ion images of m/z 703.57 
(SM(d18:1/16:0)) in red and m/z 744.57 PC (p-16:0/18:1) in green. (C) low-magnification (0.4x) H&E staining 
of serial section. (D,E) High magnification (4.0x) of H&E staining showing areas of ILN (left) and UN (right) 
from serial section. (F) Representative spectra of the ILN and UN regions from the positive (top) and negative 
ionization modes (bottom), intensities are relative. Lipid species identified are described in Table 1, with MS/MS 
spectra available in Supplemental Figures. a.i. = arbitrary intensity.
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MSI data. The mTRG calculated from MSI data was compared to the pathologist’s grading in order to stratify 
patients according to their OS and DFS and found to have a strong correlation and good predictive power. By 
introducing a computational method based on numeric MSI data we start to unify patient response grading, and 
move towards a well-defined synoptic reporting tool.
Our approach to data treatment relies on histopathology correlated MSI segmentation to define our clas-
sification groups and is advantageous when compared to histology driven MSI approaches. The latter selects 
ROIs for MSI analysis based on outside annotation post-MSI, ignoring unannotated pixels, where our approach 
includes the entirety of the MSI data available in the analysis, reducing error and increasing statistical power for 
inter-sample comparison. Although similar approaches have been described before to distinguish cancer lesions 
from adjacent normal tissue using lipid signal intensities, previous studies have not partitioned the cancer lesions 
into their component histologies in the depth described here33,40. The inclusion of all of the regions is beneficial as 
it describes the tumor burden and the tumor microenvironment. Assessing the whole lesion is important because 
cancer lesions are composed of multiple tissue types and cancer progression and regression is a dynamic process 
with tissue composition changes reflecting the status of the lesion.
The clinical application of MSI lipid signatures goes beyond pathological grading as it can serve as a valuable 
tool for refining current grading parameters and the discovery of candidate biomarkers. For example, within the 
areas of necrosis we identified C16 ceramide and C16 C1P as biomarkers of UN and ILN, respectively. C16 cer-
amide has been described as having tumor suppressor activity (having both anti-proliferative and pro-apoptotic 
activities) while in contrast C1P has pro-survival and anti-apoptotic activity, making these lipids attractive bio-
marker candidates for response to therapy41,42. It has been reported that high levels of C1P, which stimulates cell 
division and inhibits apoptosis, is toxic and can kill cells43. Alongside the ceramides, plasmalogens were identi-
fied in the necrosis areas. Although found ubiquitously in human cells, they have not been previously described 
in cancer or necrosis processes, unlike other ether lipids. In addition, they have been reported to be lower in 
abundance in liver tissue compared to other organs43,44. Interestingly, within our data set we identified PE (phos-
phoethanolamine) plasmalogens to be associated with both tumor areas and areas of inflammation, whereas PC 
plasmalogens are exclusively abundant in areas of UN. Current research indicates PE plasmalogens as the precur-
sor to PC plasmalogens as no plasmenylcholine desaturase enzyme has been described. Compared to UN, we find 
minimal PC plasmalogen signal in surrounding liver tissue. The function of these lipids in the specific histologies 
opens further areas of research. The ability to distinguish between UN and ILN is extremely important and not 
always obvious when examining CRCLMs histologically. We have identified unique lipid biomarkers for each of 
these tissue types. In fact we are able to identify ILN areas within UN that has been graded by pathologists to be 
entirely UN. These findings warrant investigation in a larger series of patients to determine if it impacts prognosis 
or response to therapeutic interventions as well as to describe the relationship between all of the lipids present in 
the two types of necrosis.
From a technical standpoint, classification based on MSI data will be key in clinical analysis. It will not be 
practical for a routine clinical pathology lab to examine MSI data ion by ion. Furthermore, many molecules 
detected by MSI are generic and will be expressed by several types of cells, with changes in their relative abun-
dance distinguishing histologies. By building a larger more heterogeneous spectral library with various types of 
cancers MSI could be used for diagnostic purposes in differentiating cancer type based on lipid profiles. Although 
the basis of this study was MSI data of lipids, lipids can be analysed by other MS systems, most notably LC-MS. 
LC-MS is not yet suitable for high throughput spatially resolved analysis of tissue lipids, but provides a deeper 
coverage of lipids. Surface extraction of lipids from tissue into an LC-MS may give the depth of lipidome coverage 
to fully map the metabolomic pathways in tumors previously only hinted at by MSI.
mTRG
MSI lipid signature profile
Area viable tumor + UN (%)
Area fibrosis + inflammation 
(%)
1 0 0–100
2 < 7* 0–100
3 ≥ 7 and < 50 ≥ 50
4 ≥ 50 ≥ 5
5 ≥ 50 0–5
Table 2.  Algorithm used for mTRG Published grading guidelines used for scoring all specimens (n = 52). 
*7% was used as cutoff point to correlate with ‘rare’ tumor foci by a clinical pathologist.
Pathologist 1 Pathologist 2 MALDI MSI
Pathologist 1 0.7361 0.8121
Pathologist 2 0.7361 0.6227
MALDI MSI 0.8121 0.6227
Average 0.7741 0.6794 0.7174
Table 3.  Correlation of pathologist and MSI mTRG (n = 52). Showing a high overall correlation of MSI 
based grading scores with the two pathologists (r = 0.717, p < 0.0001). P < 0.0001 for all correlations.
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This study supports an evidence-based model for decision making in regards to diagnosis, prognosis and 
intervention for CRCLM. We demonstrate functional linkages between MSI and histopathology and the utility 
of this “omics” technology in the clinical setting as a companion diagnostic and prognostic tool for pathologists 
and clinicians. Finally, using lipidomics we have uncovered a novel set of markers (ceramides and plasmalogens) 
to start investigating the mechanism of treatment effects and possibly novel drug targets. The introduction of MSI 
into the clinic and as a new tool for biomarker discovery will dramatically change the field of molecular pathology.
Figure 5. Kaplan–Meier survival analysis for the three response groups stratified according to pathological 
grading as observed by two independent Pathologists and by MSI. Only chemotherapy treated patients 
were included in survival analysis (n = 35). Pathologist 2 assessed 3 lesions to be too small for pathological 
evaluation. No significant differences between the three observations for each response group as assessed by 
Log-rank (Mantel-Cox) test. *Remaining observations censored.
www.nature.com/scientificreports/
1 0Scientific RepoRts | 6:36814 | DOI: 10.1038/srep36814
Methods
Standard Protocol Approvals, Registrations, and Patient Consents. The study was done in accord-
ance with the guidelines approved by McGill University Health Centre Institutional Review Board (IRB). A prior 
written informed consent was obtained from all the subjects to participate in the study.
Clinical Data. This retrospective study included a total of 52 lesions from 50 patients. Resections were pre-
formed between November 2011 and July 2014. Clinical data was collected for each patient through the locally 
established hospital database and medical records. Included within the data are demographics, primary and met-
astatic disease characteristics, relevant laboratory results, chemotherapy and co-morbidities. As shown in the 
supplemental Table S3, median age of diagnosis was 63 (range 31–81) years. Rectal cancer accounted for 34% of 
the cases. Approximately two thirds (64%) of the patients had synchronous liver metastasis (developed metastasis 
within a year of diagnosing the primary). Seventeen lesions were chemo-naive while the rest received neoadjuvant 
chemotherapy with an average of 7 cycles (Range 3–28). Estimated 1 and 3-year OS is 100% and 82.6% respec-
tively. Twenty-seven (54%) of patients had recurrence in the liver, estimated 1-year and 3-year DFS is 49.9% and 
44.4% respectively (26.5 months mean follow up duration).
Tissue sample acquisition. Informed consent was obtained from all patients through the McGill University 
Health Centre (MUHC) Liver Disease Biobank (LDB: MUHC research ethics board approved protocol). Surgical 
specimens were procured and released to the Biobank immediately after the pathologist’s confirmation of car-
cinoma and surgical margins. The specimens were frozen, within 30 minutes, according to the LDB standard 
operating procedures and processed as previously described45.
Histochemical Staining. Frozen tissues were cut using a cryostat at 10 μ m, and stored at − 80 °C in tightly closed 
boxes until staining. Before use, the slides were allowed to dry on the benchtop for 10 minutes at room tempera-
ture and then fixed for 60 minutes in freshly made 4% formaldehyde dissolved in 0.1 M phosphate buffer at pH 7.2. 
Comparative topography assays were performed between MSI and different histological stains: Apolipoprotein 
F (ApoF), ISH, PLTP ISH, alcian blue (AB)46, H&E, and Ki67 immuno-staining47, of the training set. ApoF ISH 
is hepatocyte-specific, defining regions of liver adjacent to the tumor area; PLTP ISH labeling revealed the con-
centration of macrophages within or around the tumor; AB stains areas of the metastatic lesions that contain 
mucin; H&E staining provided basic histological information for MSI correlation and pathological grading; Ki67 
immuno-staining identified tumor cells with cell cycle activity.
In situ hybridization. In situ hybridization (ISH) was performed with [35S]-labeled riboprobes synthesized 
in vitro from DNA Templates. Briefly, mouse Apolipoprotein F (ApoF, GenBank AF411832.1) DNA template 
of 675 bp was produced by PCR using sense gataccagatgcagacctca and antisense gttcgtcgttgttgacaaga primers. 
Human phospholipid transfer protein (PLTP, GenBank NM_006227.3) DNA Template of 884 bp was produced 
using GAAGAGCGGATGGTGTATGT (sense) and TGGTGGACGGACTGTAATTG (antisense) primers. 
Sequences recognized by SP6 Polymerase (5′ -GCATTAATTTAGGTGACACTATAGAAGCG-3′ ) were attached 
to antisense and T7 Polymerase (5′ -GCGCTATAATACGACTCACTATAGGGAGA-3′ ) to sense primers. 
Following hybridization, the results were visualized by x-ray film autoradiography showing anatomical level 
topography and emulsion autoradiography showing cellular level ISH labeling. Figure S2 represents the staining 
of the training set lesions.
Pathological Evaluation Methods. The following methods were used and compared to evaluate our lipid 
signatures:
(i)  Modified tumor regression grading (mTRG): All 52 lesions were stained (detailed in Supplement Figure S2) 
to identify areas and relative percentage of viable liver cells, fibrosis, inflammation, mucin, usual necrosis 
and infarct like necrosis. Two independent pathologists assessed modified Tumor Regression Grade (mTRG) 
as described by Chang et al. for every sample using high-resolution H&E slide scans (Table S2)23. For the 
mTRG grading UN was defined as containing nuclear debris and bordered by viable cells whereas ILN was 
defined as being a large confluent areas of eosinophilic cytoplasmic remnant located centrally within the 
lesion without the presence of nuclear debris. Briefly, mTRG1 is defined by the absence of tumor cells and 
replaced by fibrosis and ILN; mTRG2 contains rare scattered residual tumor cells with predominant fibrosis 
and the presence of both ILN and UN; mTRG3 contains more residual tumor cells throughout predominant 
fibrosis and UN; mTRG4 contains large amounts of tumor cells and intermingled UN which predominates 
over fibrosis and ILN; and mTRG5 contains tumor cells and intermingles UN without any fibrosis. The high-
er the grade the worse the response.
(ii)  Pathological response: All samples were grouped into 3 response groups based on their mTRG score. Major 
response includes: grades 1 and 2, partial response: grade 3, and minor response: grades 4 and 520.
Statistical Analysis. Survival probabilities were calculated by the Kaplan-Meier method and compared by the 
log rank (Mantel-Cox) test. A p value of less than 0.05 was considered statistically significant. All analysis was 
performed using JMP.11 software. Overall survival was calculated from the date that the metastases were detected 
to the date of last follow-up. Disease free survival was calculated from the date of surgical intervention to the date 
of recurrence or last follow-up if patient was still disease free.
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Mass Spectrometry. MALDI-MSI Tissue Sectioning and Sample Preparation. Tissue sectioning and prepa-
ration was performed as previously described45. Briefly, tissue cryo-sections of 10 μ m were thaw-mounted onto 
ITO coated glass slides (Delta Technologies, Loveland, CO) and 1,5-diaminonapthalene (DAN) matrix (Sigma 
Aldrich, Oakville, CA) was sublimated on the slide.
MALD-MSI instrument parameters. MSI in both positive and negative polarity of each tissue section was per-
formed using a Bruker MALDI-TOF/TOF Ultraflextreme as previously described with only minor changes45. 
Briefly, 150 laser shots were summed per array position, with 100 μ m of resolution for every acquisition. Negative 
ionization mode was acquired using an offset of 50 μ m to positive ionization mode MSI grid array. MALDI laser 
influence and ion accelerating voltages in reflectron mode were optimized for the sample set. The mass range was 
m/z 460–1200 for both ionization modes.
On tissue MALDI-MS/MS. MS/MS measurements for species detected in positive mode were acquired in 
LIFT-TOF/TOF mode of the Ultraflexetreme and with a Bruker Solarix 15 T FT-ICR using dried droplet spot-
ting of 2,5-dihydroxyacetophenone doped with 100 mM Lithium Trifluoroacetate for improved fragmentation48 
whereas negative species were directly fragmented after DAN sublimation. MS/MS data were processed using 
flexAnalysis v3.3 software (Bruker Daltonics, Billerica, MA). The LIPID MAPS database was used for comparing 
accurate mass and obtaining lipid structures for the determination of fragmentation pathways49.
MALDI-MSI data analysis. Data was displayed using flexImaging 4.1 (Bruker Daltonics, Billerica, Massachusetts). 
Data was exported to imzML format for processing50. Spectral smoothing using the Savitzky-Golasky algorithm, 
Total Ion Current (TIC) normalization, and peak picking using a signal-to-noise ratio of 3.0 were performed 
using the MALDIquant package in the R environment51. Generated peak intensity data were segmented using 
spatially aware K-means (r = 1, k = 7)52, as implemented in the Cardinal MSI R package53. Partial Least Squares–
Discriminant Analysis (PLS-DA) and ROC analysis were performed in the R environment using the mixOmics54 
and ROCR55 packages, respectively.
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